Reduced Dose of Imatinib for Patients with Chronic Myeloid Leukemia and Low Body Surface Area

Publisher： Karger

E-ISSN： 1421-9662|118|4|219-221

ISSN： 0001-5792

Source： Acta Haematologica, Vol.118, Iss.4, 2007-11, pp. : 219-221

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

The Importance of Body Surface Area at Baseline and during Treatment in Chronic Myeloid Leukemia Patients Treated with Imatinib

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 57-58

Karger

Access to resources Recommend Favorite

Imatinib Mesylate Dose Adjustment Based on Body Surface Area for CML Chronic Phase Patients Intolerant to Standard Dosage

By  

Acta Haematologica, Vol. 134, Iss. 1, 2015-04 ,pp. : 59-68

Karger

Access to resources Recommend Favorite

Incidence of persistent/late chronic anemia in newly diagnosed patients with chronic myeloid leukemia responsive to imatinib

By  

AMERICAN JOURNAL OF HEMATOLOGY, Vol. 90, Iss. 2, 2015-02 ,pp. : 105-108

John Wiley & Sons Inc

Access to resources Recommend Favorite

Tolerability and efficacy of pegylated interferon‐α‐2a in combination with imatinib for patients with chronic‐phase chronic myeloid leukemia

By  

CANCER, Vol. 119, Iss. 24, 2013-12 ,pp. : 4284-4289

John Wiley & Sons Inc

Access to resources Recommend Favorite

Changes in Expression of Apoptosis-Related Genes Are Linked to the Molecular Response to Imatinib Treatment in Chronic-Phase Chronic Myeloid Leukemia Patients

By  

Acta Haematologica, Vol. 117, Iss. 2, 2006-11 ,pp. : 83-90

Karger

Access to resources Recommend Favorite